Literature DB >> 31401717

The need for an adapted initiation nomogram during Fiix prothrombin time monitoring of warfarin.

Pall T Onundarson1,2, Brynja R Gudmundsdottir3.   

Abstract

The new Fiix prothrombin time (Fiix-PT) and its derived Fiix-normalized ratio (Fiix-NR) is affected only by reductions in coagulation factors (F) II and X, the two factors responsible for the antithrombotic effect of vitamin K antagonists (VKA). Due to insensitivity to reductions in the short half-life FVII, the Fiix-NR rises later than standard PT-INR during warfarin initiation. To describe a warfarin initiation nomogram adapted for monitoring with Fiix-NR, anticoagulation development was assessed during use of standard PT-INR based initiation nomogram and after adapting the initiation nomogram for Fiix-NR monitoring. Normalized ratios were retrospectively assessed in consecutive warfarin naïve patients during their first 60 days of warfarin intake for one year prior to (PT-INR period) and for one year after replacing the PT-INR with the Fiix-NR (Fiix-NR period). The INR target was NR 2.0-3.0. We evaluated 160 patients monitored with PT-INR and dosed with the PT-nomogram, 57 monitored with Fiix-INR but dosed with PT-nomogram, and 163 Fiix-NR monitored patients dosed using a new Fiix nomogram. Mean PT-INR over 2.0 was reached on day 7 during the PT-period and remained around 2.5 thereafter. When the PT-nomogram continued in use during Fiix-monitoring significantly more patients became overanticoagulated during days 11-29. After the nomogram was modified to respond to rising Fiix-NR with larger initial dose reduction, the mean Fiix-NR reached over 2 on day 8-9 and remained around 2.5 thereafter. When warfarin is monitored with Fiix-NR, an adjusted dosing nomogram should be used during initiation to prevent early overanticoagulation.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31401717     DOI: 10.1007/s11239-019-01928-4

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  13 in total

1.  Simplified method for international normalized ratio (INR) derivation based on the prothrombin time/INR line: an international study.

Authors:  Leon Poller; Saied Ibrahim; Michelle Keown; Albert Pattison; Jørgen Jespersen
Journal:  Clin Chem       Date:  2010-08-26       Impact factor: 8.327

Review 2.  Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Walter Ageno; Alexander S Gallus; Ann Wittkowsky; Mark Crowther; Elaine M Hylek; Gualtiero Palareti
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

3.  The control of dicumarol therapy and the quantitative determination of prothrombin and proconvertin.

Authors:  P A OWREN; K AAS
Journal:  Scand J Clin Lab Invest       Date:  1951       Impact factor: 1.713

4.  Reduced anticoagulation variability in patients on warfarin monitored with Fiix-prothrombin time associates with reduced thromboembolism: The Fiix-trial.

Authors:  Alma Rut Oskarsdóttir; Brynja R Gudmundsdottir; Olafur S Indridason; Sigrun H Lund; David O Arnar; Einar S Bjornsson; Magnus K Magnusson; Hulda M Jensdottir; Brynjar Vidarsson; Charles W Francis; Pall T Onundarson
Journal:  J Thromb Thrombolysis       Date:  2017-05       Impact factor: 2.300

5.  The relative importance of the factors II, VII, IX and X for the prothrombinase activity in plasma of orally anticoagulated patients.

Authors:  M Xi; S Béguin; H C Hemker
Journal:  Thromb Haemost       Date:  1989-09-29       Impact factor: 5.249

6.  During warfarin induction, the Fiix-prothrombin time reflects the anticoagulation level better than the standard prothrombin time.

Authors:  P I Jonsson; L Letertre; S J Juliusson; B R Gudmundsdottir; C W Francis; P T Onundarson
Journal:  J Thromb Haemost       Date:  2016-11-30       Impact factor: 5.824

7.  Fiix-prothrombin time versus standard prothrombin time for monitoring of warfarin anticoagulation: a single centre, double-blind, randomised, non-inferiority trial.

Authors:  Páll T Onundarson; Charles W Francis; Olafur S Indridason; David O Arnar; Einar S Bjornsson; Magnus K Magnusson; Sigurdur J Juliusson; Hulda M Jensdottir; Brynjar Vidarsson; Petur S Gunnarsson; Sigrun H Lund; Brynja R Gudmundsdottir
Journal:  Lancet Haematol       Date:  2015-05-25       Impact factor: 18.959

8.  Critical role of factors II and X during coumarin anticoagulation and their combined measurement with a new Fiix-prothrombin time.

Authors:  Brynja R Gudmundsdottir; Charles W Francis; Alexia M Bjornsdottir; Moa Nellbring; Pall T Onundarson
Journal:  Thromb Res       Date:  2012-01-04       Impact factor: 3.944

9.  Mechanism of the anticoagulant effect of warfarin as evaluated in rabbits by selective depression of individual procoagulant vitamin K-dependent clotting factors.

Authors:  A Zivelin; L V Rao; S I Rapaport
Journal:  J Clin Invest       Date:  1993-11       Impact factor: 14.808

Review 10.  Fiix-prothrombin time monitoring improves warfarin anticoagulation outcome in atrial fibrillation: a systematic review of randomized trials comparing Fiix-warfarin or direct oral anticoagulants to standard PT-warfarin.

Authors:  P T Onundarson; D O Arnar; S H Lund; B R Gudmundsdottir; C W Francis; O S Indridason
Journal:  Int J Lab Hematol       Date:  2016-05       Impact factor: 2.877

View more
  1 in total

1.  Ignoring instead of chasing after coagulation factor VII during warfarin management: an interrupted time series study.

Authors:  Alma R Oskarsdottir; Brynja R Gudmundsdottir; Hulda M Jensdottir; Bjorn Flygenring; Ragnar Palsson; Pall T Onundarson
Journal:  Blood       Date:  2021-05-20       Impact factor: 22.113

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.